Fundraising FoxPhenomics Health
Plymouth, US · 1 known investors
Find your way into Phenomics Health
Sign up to see every warm intro you have to Phenomics Health
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Phenomics Health team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Phenomics Health builds a medication-response intelligence platform that combines high-complexity clinical laboratory testing, pharmacogenomics, pharmacometabolomics, and AI-enabled analytics to support precision prescribing and medication decisions. It serves clinicians, payors, providers, and life-sciences partners in the precision-medicine space.
Founders & leadership
BD
Brian D. AtheyCo-founder
DJ
Daniel JasewiczCompany Leadership (Strategy & Commercialization)Daniel Jasewicz is a healthcare executive with experience in precision medicine, pharmacogenomics, and AI-enabled clinical diagnostics platforms. He has led organizations building EHR-integrated diagnostic systems and decision-support tools in regulated laboratory environments, and currently leads strategy and commercialization at Phenomics Health.
GH
Gerry HigginsScientific Strategy LeadGerry Higgins is Vice President at Phenomics Health, where he applies expertise in pharmacogenomics and disease genetics to precision medicine. He has over 35 years of experience in biomedical research and clinical informatics, and holds academic roles at PhenomicsAI and the University of Michigan Medical School.
AA
Alex AdeTechnology & Data Science LeadAlex Ade is Technology & Data Science Lead at Phenomics Health, where he focuses on building data and AI-enabled platforms for precision medicine. He has a background in software engineering and systems design, with experience leading the architecture and delivery of scalable platforms in healthcare settings.
PW
Pamela WeirNamed on SEC filing
LW
Lew WallaceNamed on SEC filing
FD
F. David ParkerNamed on SEC filing
JM
Jarrett MillsapsNamed on SEC filing
JS
James S. BurnsFounder
Investors · 1
Reported raises · per SEC filings
Form D private placements$11.5M disclosed across 1 round · 2022
▶$11.5MraisedOct 2022 · 33 investors · OtherRule 506(b)
▶$11.5MraisedOct 2022 · 33 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Pamela WeirDirector
- Lew WallaceDirector
- F. David ParkerDirector
- Jarrett MillsapsDirector
- James S. BurnsExecutive Officer, Director
- Offering amount
- $19.5M
- Amount sold
- $11.5M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
Genomics PlcGenomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers. It serves life sciences companies and healthcare systems through its Life Sciences and Health & Wellness divisions.
PhinomicsPhinomics is a cancer drug discovery platform that captures extrachromosomal circular DNA (the "Circulome") at high resolution from matched tumor and normal patient samples, integrating it with DNA, RNA, epigenetics, and proteomics into a multi-omic knowledge graph. It applies explainable AI to this data to identify novel therapeutic targets, resistance mechanisms, and patient stratification biomarkers for oncology therapeutics development.
Phenomic AIPhenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.
Phenomix SciencesPhenomix Sciences applies data analytics and patient data to enable precision obesity medicine, aiming to guide treatment decisions for anti-obesity medications such as GLP-1s and reduce care costs. Its platform-based approach targets the healthcare market for obesity treatment.
NeoGenomicsNeoGenomics develops diagnostic tests and tools for cancer care, including tests for immunotherapy response monitoring, therapy selection, and minimal residual disease detection.
TagomicsTagomics develops multimodal technologies for precision medicine and next-generation diagnostics. The company is based in Cambridge and focuses on improving patient outcomes through advanced diagnostic technologies.
HelixHelix is a population genomics company that provides an end-to-end platform to integrate genomic data into clinical care, research, and therapeutic development. It partners with health systems, providers, payers, life sciences organizations, and patients to enable genetic screening and personalized healthcare at scale.
Companies working in the same space as Phenomics Health.
In the news
Frequently asked questions
- What does Phenomics Health do?
- Phenomics Health builds a medication-response intelligence platform that combines high-complexity clinical laboratory testing, pharmacogenomics, pharmacometabolomics, and AI-enabled analytics to support precision prescribing and medication decisions. It serves clinicians, payors, providers, and life-sciences partners in the precision-medicine space.
- Who founded Phenomics Health?
- Phenomics Health was founded by Brian D. Athey.
- Who are Phenomics Health's investors?
- Phenomics Health's investors include Solas BioVentures.
- How much funding has Phenomics Health raised?
- Phenomics Health has disclosed $11.5M raised across 1 round.
- Where is Phenomics Health headquartered?
- Phenomics Health is headquartered in Plymouth, US.